Table II.
Association between body mass index (BMI) and hormones/peptides: Means ± SE among a sample of 710 women with breast cancer
| BMI < 25 | BMI: 25 – 29.9 | BMI ≥ 30 | P for trend | |
|---|---|---|---|---|
| Mean ± SE (n = 284) | Mean ± SE (n = 216) | Mean ± SE (n = 210) | ||
| C-Peptide (ng/mL) | ||||
| Unadjusted | 1.83 ± 0.06 | 2.37 ± 0.07a | 2.82 ± 0.07b,c | .0001 |
| Adjusted1 | 1.79 ± 0.06 | 2.34 ± 0.06a | 2.91 ± 0.07b,c | .0001 |
| Adjusted2 | 1.81 ± 0.06 | 2.34 ± 0.06a | 2.88 ± 0.07b,c | .0001 |
| Leptin (ng/mL) | ||||
| Unadjusted | 12.5 ± 0.8 | 23.5 ± 0.9a | 42.2 ± 0.9b,c | .0001 |
| Adjusted1 | 12.8 ± 0.8 | 23.6 ± 0.9a | 41.6 ± 0.9b,c | .0001 |
| Adjusted2 | 13.0 ± 0.8 | 23.7 ± 0.9a | 41.3 ± 0.9b,c | .0001 |
| IGF-I (ng/mL) | ||||
| Unadjusted | 144.1 ± 3.4 | 137.8 ± 3.9a | 114.9 ±3.9b,c | .0001 |
| Adjusted1 | 142.5 ± 3.1 | 136.5 ± 3.5a | 118.4 ±3.6b,c | .0001 |
| Adjusted2 | 142.3 ± 3.4 | 136.5 ± 3.5a | 118.7 ±3.6b,c | .0001 |
| IGFBP-3 (ug/mL) | ||||
| Unadjusted | 4.09 ± 0.06 | 4.10 + 0.07 | 4.04 ± 0.07 | .57 |
| Adjusted1 | 4.10 ± 0.06 | 4.08 ± 0.06 | 4.05 ± 0.07 | .57 |
| Adjusted2 | 4.10 ± 0.06 | 4.08 ± 0.06 | 4.05 ± 0.07 | .60 |
| IGF-I:IGFBP-3 (ng/mL) | ||||
| Unadjusted | 35.1 ± 0.7 | 33.6 ± 0.8a | 28.6 ± 0.8b,c | .0001 |
| Adjusted1 | 34.7 ± 0.6 | 33.4 ± 0.7a | 29.4 ± 0.8b,c | .0001 |
| Adjusted2 | 34.7 ± 0.6 | 33.4 ± 0.8a | 29.4 ± 0.7b,c | .0001 |
1
Adjusted for study site, age, ethnicity, education, menopausal status, disease stage, adjuvant treatment, tamoxifen use, type 2 diabetes, and smoking status.
2
Adjusted for all the above covariates including sports/recreational MET-hr/week.
a
BMI 25–29.9 significantly different from BMI < 25, p < .05.
b
BMI ≥30 significantly different from BMI < 25, p < .05.
c
BMI ≥30significantly different from BMI 25.0 – 29.9, p < .05.